

V:\T&S\HDC\Trial_management\Publications\Publicaties\HOVON publications.doc

Table of contents

Acute lymphoblastic leukemia (ALL) 2

Acute myeloid leukemia (AML), Acute promyelocytic leukemia (APL) and Myelodysplastic syndromes (MDS)
..... 5

Chronic Lymphoid Leukemia (CLL) 18

Chronic Myeloid Leukemia (CML) 19

Follicular lymphoma (FL) 21

Hairy cell leukemia (HCL) 22

Mantle cell lymphoma (MCL) 23

Multiple myeloma (MM) and amyloidosis 24

Non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) 30

Stem cell transplantation 34

Supportive care 35

General 36

Note:

For each of these publications, a .PDF-file is available at the HDC, unless specified otherwise. These can be found in V:\T&S\HDC\Trial_management\Publications\Publicaties; by year of publication (of printed version), by trial, and within working group by trial.

Acute lymphoblastic leukemia (ALL)

HOVON 5 ALL (03/88 - 01/93)

J.M. de Bont, B. van der Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld and R. Pieters. [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols] [Article in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*. 2005; 149: 400-406 (joint publication with HOVON-18)

J.M. de Bont, B. van der Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld and R. Pieters. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. *Leukemia*. 2004; 18: 2032-2035 (joint publication with HOVON-18)

A.W. Dekker, M.B. van't Veer, W. Sizoo, H.L. Haak, J. van der Lelie, G. Ossenkoppele, P.C. Huijgens, H.C. Schouten, P. Sonneveld, R. Willemze, L.F. Verdonck, W.L.J. van Putten and B. Löwenberg for the Dutch Hemato-Oncology Research Group. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. *Journal of Clinical Oncology*. 1997; 15: 476-482

M.B. van't Veer, W.L.J. van Putten, L.F. Verdonck, G.J. Ossenkoppele, B. Löwenberg, J.C. Kluin-Nelemans, P.W. Wijermans, H.C. Schouten, W. Sizoo and A.W. Dekker. Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation. *Annals of Hematology*. 1993; 66: 277-282

HOVON 18 ALL (06/93 - 02/99)

Gupta V, Richards S, Rowe J, et al; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013; 121: 339-350 (joint publication with HOVON-37)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -29, -37, -42/42A, -43, -51, -70 and -71)

J.M. de Bont, B. van der Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld and R. Pieters. [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols] [Article in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*. 2005; 149: 400-406 (joint publication with HOVON-5)

J.M. de Bont, B. van der Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld and R. Pieters. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. *Leukemia*. 2004; 18: 2032-2035 (joint publication with HOVON-5)

J.J. Cornelissen, B. van der Holt, G.E. Verhoef, M.B. van't Veer, M.H. van Oers, H.C. Schouten, G. Ossenkoppele, P. Sonneveld, J. Maertens, M. van Marwijk Kooy, M.R. Schaafsma, P.W. Wijermans, D.H. Biesma, S. Wittebol, P.J. Voogt, J.W. Baars, P. Zachée, L.F. Verdonck, B. Löwenberg and A.W. Dekker; Dutch-Belgian HOVON Cooperative Group. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. *Blood*. 2009; 113: 1375-1382 (joint publication with HOVON-37)

HOVON 37 ALL (04/99 - 11/05)

Lauw MN, Van der Holt B, Middeldorp S, Meijers JC, Cornelissen J, Biemond BJ. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. *Thromb Haemost*. 2013; 109: 663-642

Gupta V, Richards S, Rowe J, et al; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among

younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013; 121: 339-350 (joint publication with HOVON-18)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijnveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -18, -29, -42/42A, -43, -51, -70 and -71)

J.J. Cornelissen, B. van der Holt, G.E. Verhoef, M.B. van't Veer, M.H. van Oers, H.C. Schouten, G. Ossenkoppele, P. Sonneveld, J. Maertens, M. van Marwijk Kooy, M.R. Schaafsma, P.W. Wijermans, D.H. Biesma, S. Wittebol, P.J. Voogt, J.W. Baars, P. Zachée, L.F. Verdonck, B. Löwenberg and A.W. Dekker; Dutch-Belgian HOVON Cooperative Group. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. *Blood*. 2009; 113: 1375-1382 (joint publication with HOVON-18)

HOVON 70 ALL (10/05 - 08/07)

Rijnveld AW, van der Holt B, Daenen SM, Biemond BJ, de Weerd O, Muus P, Maertens J, Mattijssen V, Demuyndck H, Legdeur MC, Wijermans PW, Wittebol S, Spoelstra FM, Dekker AW, Ossenkoppele GJ, Willemze R and Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. *Leukemia*. 2011; 25: 1697-1703

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijnveld AW, Löwenberg B. and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -18, -29, -37, -42/42A, -43, -51 and -71)

HOVON 71 ALL (10/05 - 01/08)

Daenen S, van der Holt B, Dekker AW, Willemze R, Rijnveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuyndck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ; HOVON; Dutch-Belgian Cooperative Group for Hematological Oncology. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. *Leukemia*. 2012; 26:1726-1729

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijnveld AW, Löwenberg B. and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -18, -29, -37, -42/42A, -43, -51 and -70)

HOVON 74 ALL (05/06 - 10/07)

Willemze R, Cornelissen JJ, Daenen SM, Dekker AW, Muus P. Alemtuzumab voor volwassenen met een eerste of tweede recidief van acute lymfatische leukemie (HOVON 74). *Nederlands Tijdschrift voor Hematologie*. 2007; 4: 190-191

HOVON 100 ALL / EORTC 06083 (10/09 - ongoing)

Rijnveld AW, Daenen SM, Cornelissen JJ. HOVON 100: fase II/III-studie naar de tolerantie en de effectiviteit van toevoeging van clofarabine aan de standaardbehandeling voor patiënten met acute lymfatische leukemie. *Nederlands Tijdschrift voor Hematologie*. 2009; 6: 228-230

Reviews & guidelines

Rijneveld AW, Cornelissen JJ. Acute lymfatische leukemie: nieuwe behandelingsmogelijkheden. *Nederlands Tijdschrift voor Hematologie*. 2013; 10: 226-232

Acute myeloid leukemia (AML), Acute promyelocytic leukemia (APL) and Myelodysplastic syndromes (MDS)**HOVON 1 AML (11/84 - 06/87)**

B. Löwenberg, W.L.van Putten, I.P. Touw, R. Delwel and V. Santini. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. *The New England Journal of Medicine*. 1993; 328: 614-619 (joint publication with HOVON-4)

H.C. Schouten, W.L.J. van Putten, A. Hagemeijer, G.H. Blijham, P. Sonneveld, R. Willemze, R. Slater, J. van de Lely, L.F. Verdonck and B. Löwenberg. The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation. *Bone Marrow Transplantation*. 1991; 8: 377-381 [no .PDF; abstract only]

B. Löwenberg, W.L.J. van Putten, L.F. Verdonck, A.W. Dekker, G.C. de Gast, R. Willemze, F.E. Zwaan, J. Abels, P. Sonneveld, J. van der Lelie, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. *Hamatol Bluttransfus*. 1990; 33: 655-660 [no .PDF; abstract only]

B. Löwenberg, L.J. Verdonck, A.W. Dekker, R. Willemze, F.E. Zwaan, M. de Planque, J. Abels, P. Sonneveld, J. van der Lelie, R. Goudsmit, W.L.J. van Putten, W. Sizoo, A. Hagenbeek and G.C. de Gast. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. *Journal of Clinical Oncology*. 1990; 8: 287-294

G.C. de Gast, B. Löwenberg, R. Willemze, J. van der Lelie, L.F. Verdonck, A. Hagenbeek, W.L. van der Putten, F.E. Zwaan and R. Goudsmit. Autologous BMT in acute myeloid leukaemia in first remission (Dutch prospective study). *Folia Haematol Int Mag Klin Morphol Blutforsch*. 1989; 116: 499 [no .PDF; no abstract]

HOVON 4/4A AML (HO04: 07/87 - 06/95; HO04A: 10/90 - 11/94)

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. *J Clin Oncol*. 2013; 31: 95-103 (joint publication with HOVON-4/4A, -29, -42/42A, -43 and -92)

A. Leunis, W.K. Redekop, K.A.G.M. van Montfort, B. Löwenberg and C.A. Uyl-de Groot. The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia. *PharmacoEconomics*. 2013; 31: 605–621 (joint publication with HOVON-29 and -42/42A)

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013; 122: 1576-1582 (joint publication with HOVON-29, -42/42A and -92)

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013; 121: 2424-2431 (joint publication with HOVON-29, -42/42A, -43 and -92)

Breems DA, Van Putten WL, Löwenberg B. The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. *Blood*. 2013; 121: 3056-3057 (joint publication with HOVON-29 and -42/42A)

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ,

Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *Journal of Clinical Oncology*. 2012; 30: 2140-2146 (joint publication with HOVON-29 and -42/42A)

Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Löwenberg B and Valk PJ. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. *Blood*. 2011; 118: 1069-1076 (joint publication with HOVON-29 and -42)

Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J and Ganser A. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. *Blood*. 2011; 117: 4561-4568 (joint publication with HOVON-29 and -42)

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkuppele G, Vellenga E, van den Berg-de Ruitter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B and Döhner H. Clinical, molecular, and prognostic significance of WHO type *inv(3)(q21q26.2)/t(3;3)(q21;q26.2)* and various other 3q abnormalities in acute myeloid leukemia. *Journal of Clinical Oncology*. 2010; 28: 3890-3898 (joint publication with HOVON-29, -42 and -43)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-18, -29, -37, -42/42A, -43, -51, -70 and -71)

Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwien K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkuppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K and Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *Journal of Clinical Oncology*. 2010; 28: 2101-2107 (joint publication with HOVON-29 and -42)

Figuroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, Valk PJ, Löwenberg B, Delwel R and Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell*. 2010; 17: 13-27 (joint publication with HOVON-29, -42 and -43)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (joint publication with HOVON-10, -29, -32, -42 and -43)

D.A. Breems, W.L. van Putten, G.E. de Greef, S.L. van Zelderen-Bhola, K.B. Gerssen-Schoorl, C.H. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeijer, H.B. Beverloo and B. Löwenberg. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *Journal of Clinical Oncology*. 2008; 26: 4791-4797 (joint publication with HOVON-29 and -42)

J.J. Cornelissen, W.L.J. van Putten, L.F. Verdonck, M. Theobald, E. Jacky, S.M. Daenen, M. van Marwijk Kooy, P. Wijermans, H. Schouten, P.C. Huijgens, H. van der Lelie, M. Fey, A. Ferrant, J. Maertens, A. Gratwohl and B. Löwenberg. Myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom? results of a HOVON/SAKK donor versus no donor analysis. *Blood*. 2007; 109: 3658-3666 (joint publication with HOVON-29 and -42)

R.G. Verhaak, C.S. Goudswaard, W. van Putten, M.A. Bijl, M.A. Sanders, W. Hagens, A.G. Uitterlinden, C.A. Erpelinck, R. Delwel, B. Löwenberg and P.J. Valk. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood*. 2005; 106: 3747-3754 (joint publication with HOVON-29 and -32)

G.E. de Greef, W.L. van Putten, M. Boogaerts, P.C. Huijgens, L.F. Verdonck, E. Vellenga, M. Theobald, E. Jacky and B. Löwenberg; The Dutch-Belgian Hemato-Oncology Co-operative Group HOVON; The Swiss

Group for Clinical Cancer Research SAKK. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. *British Journal of Haematology*. 2005; 128: 184-191 (joint publication with HOVON-29)

D.A. Breems, W.L. van Putten, P.C. Huijgens, G.J. Ossenkoppele, G.E. Verhoef, L.F. Verdonck, E. Vellenga, G.E. de Greef, E. Jacky, J. van der Lelie, M.A. Boogaerts and B. Löwenberg. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *Journal of Clinical Oncology*. 2005; 23: 1969-1978 (joint publication with HOVON-29)

D.A. Breems, M.A. Boogaerts, A.W. Dekker, W.L. Van Putten, P. Sonneveld, P.C. Huijgens, J. van der Lelie, E. Vellenga, A. Gratwohl, G.E. Verhoef, L.F. Verdonck and B. Löwenberg. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. *British Journal of Haematology*. 2005; 128: 59-65

S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelinck, W.L. van Putten, P.J. Valk, S. van der Poel-van de Luytgaarde, R. Hack, R. Slater, E.M. Smit, H.B. Beverloo, G. Verhoef, L.F. Verdonck, G.J. Ossenkoppele, P. Sonneveld, G.E. de Greef, B. Lowenberg and R. Delwel. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. *Blood*. 2003; 101: 837-845 (joint publication with HOVON-29 and -31)

M.M. van den Heuvel-Eibrink, E.A. Wiemer, A. Prins, J.P. Meijerink, P.J. Vossebeld, B. van der Holt, R. Pieters and P. Sonneveld. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). *Leukemia*. 2002; 16: 833-839 (joint publication with HOVON-29)

M.M. van den Heuvel-Eibrink, E.A. Wiemer, M.J. de Boevere, B. van der Holt, P.J. Vossebeld, R. Pieters and P. Sonneveld. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. *Blood*. 2001; 97: 3605-3611 (joint publication with HOVON-29)

M.M. van den Heuvel-Eibrink, E.A. Wiemer, M.J. de Boevere, R.M. Slater, E.M. Smit, M.M. van Noesel, B. van der Holt, M. Schoester, R. Pieters and P. Sonneveld. MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. *Leukemia*. 2001; 15: 398-405 (joint publication with HOVON-29)

D.M. van der Kolk, E.G. de Vries, W.J. van Putten, L.F. Verdonck, G.J. Ossenkoppele, G.E.G. Verhoef and E. Vellenga. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. *Clinical Cancer Research*. 2000; 6: 3205-3214 (joint publications with HOVON-29)

B. Löwenberg, M.A. Boogaerts, S.M.G.J. Daenen, G.E.G. Verhoef, A. Hagenbeek, E. Vellenga, G.J. Ossenkoppele, P.C. Huijgens, L.F. Verdonck, J. van der Lelie, J.J. Wielenga, H.C. Schouten, J. Gmür, A. Gratwohl, U. Hess, M.F. Fey and W.L.J. van Putten. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. *Journal of Clinical Oncology*. 1997; 15: 3496-3506

M.M. van den Heuvel-Eibrink, B. van der Holt, P.A. te Boekhorst, R. Pieters, M. Schoester, B. Lowenberg and P. Sonneveld. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. *British Journal of Haematology*. 1997; 99: 76-83 (joint publication with HOVON-9)

S. Daenen, B. Löwenberg, P. Sonneveld, W.L.J. van Putten, G. Verhoef, L.F. Verdonck, M. van Veldhoven and P.C. Huijgens on behalf of the Dutch Hematology-Oncology Working Group for Adults (HOVON). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. *Leukemia*. 1994; 8: 6-10 [no .PDF; abstract only]

B. Löwenberg, W.L. van Putten, I.P. Touw, R. Delwel and V. Santini. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. *The New England Journal of Medicine*. 1993; 328: 614-619 (joint publication with HOVON-1)

HOVON 9 AML / EORTC (04/86 - 11/93)

B. Löwenberg, S. Suci, E. Archimbaud, H. Haak, P. Stryckmans, R. de Cataldo, A.W. Dekker, Z.N. Berneman, A. Thyss, J. van der Lelie, P. Sonneveld, G. Visani, G. Fillet, M. Hayat, A. Hagemeijer, G. Solbu and R. Zittoun. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Randomized phase III study AML-9. *Journal of Clinical Oncology*. 1998; 16: 872-878

M.M. van den Heuvel-Eibrink, B. van der Holt, P.A. te Boekhorst, R. Pieters, M. Schoester, B. Lowenberg and P. Sonneveld. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. *British Journal of Haematology*. 1997; 99: 76-83 (joint publication with HOVON-4)

HOVON 10 MDS (08/92 - 05/95)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (joint publication with HOVON-4, -29, -32, -42 and -43)

G.J. Ossenkoppele, B. van der Holt, G.E.G. Verhoef, S.M.G.J. Daenen, L.F. Verdonck, P. Sonneveld, P.W. Wijermans, J. van der Lelie, W.L.J. van Putten and B. Löwenberg for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. *Leukemia*. 1999; 13: 1207-1213

HOVON 11 AML / EORTC 06892 (11/90 - 10/94)

C.A. Uyl-de Groot, B. Löwenberg, E. Vellenga, S. Suci, R. Willemze and F.F. Rutten. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. *British Journal of Haematology*. 1998; 100: 629-636

B. Löwenberg, S. Suci, E. Archimbaud, G. Ossenkoppele, G.E.G. Verhoef, E. Vellenga, P. Wijermans, Z. Berneman, A.W. Dekker, P. Stryckmans, H. Schouten, U. Jehn, P. Muus, P. Sonneveld, M. Dardenne and R. Zittoun on behalf of EORTC-LCG and HOVON. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). *Blood*. 1997; 90: 2952-2961

HOVON 29 AML / SAKK 30/95 (03/95 - 06/01)

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. *J Clin Oncol*. 2013; 31: 95-103 (joint publication with HOVON-4/4A, -29, -42/42A, -43 and -92)

A. Leunis, W.K. Redekop, K.A.G.M. van Montfort, B. Löwenberg and C.A. Uyl-de Groot. The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia. *PharmacoEconomics*. 2013; 31: 605-621 (joint publication with HOVON-4 and -42/42A)

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B. The

value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013; 122: 1576-1582 (joint publication with HOVON-4/4A, -42/42A and -92)

Breems DA, Van Putten WL, Löwenberg B. The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. *Blood*. 2013; 121: 3056-3057 (joint publication with HOVON-4/4A and -42/42A)

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013; 121: 2424-2431 (joint publication with HOVON-4/4A, -42/42A, -43 and -92)

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *Journal of Clinical Oncology*. 2012; 30: 2140-2146 (joint publication with HOVON-4/4A and -42/42A)

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF and Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. *Blood*. 2011; 118: 6037-6042 (joint publication with HOVON-42)

Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Löwenberg B and Valk PJ. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. *Blood*. 2011; 118: 1069-1076 (joint publication with HOVON-4/4A and -42)

Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J and Ganser A. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. *Blood*. 2011; 117: 4561-4568 (joint publication with HOVON-4/4A and -42)

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruyter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B and Döhner H. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *Journal of Clinical Oncology*. 2010; 28: 3890-3898 (joint publication with HOVON-4/4A, -42 and -43)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -18, -37, -42/42A, -43, -51, -70 and -71)

Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwien K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K and Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *Journal of Clinical Oncology*. 2010; 28: 2101-2107 (joint publication with HOVON-4/4A and -42)

Figuroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, Valk PJ, Löwenberg B, Delwel R and Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell*. 2010; 17: 13-27 (joint publication with HOVON-4/4A, -42 and -43)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a

distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (joint publication with HOVON-4, -10, -32, -42 and -43)

D.A. Breems, W.L. van Putten, G.E. de Greef, S.L. van Zelderren-Bhola, K.B. Gerssen-Schoorl, C.H. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeijer, H.B. Beverloo and B. Löwenberg. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *Journal of Clinical Oncology*. 2008; 26: 4791-4797 (joint publication with HOVON-4/4A and -42)

J.J. Cornelissen, W.L.J. van Putten, L.F. Verdonck, M. Theobald, E. Jacky, S.M. Daenen, M. van Marwijk Kooy, P. Wijermans, H. Schouten, P.C. Huijgens, H. van der Lelie, M. Fey, A. Ferrant, J. Maertens, A. Gratwohl and B. Löwenberg. Myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle aged adults: benefits for whom? results of a HOVON/SAKK donor versus no donor analysis. *Blood*. 2007; 109: 3658-3666 (joint publication with HOVON-4/4A and -42)

R.G. Verhaak, C.S. Goudswaard, W. van Putten, M.A. Bijl, M.A. Sanders, W. Hagens, A.G. Uitterlinden, C.A. Erpelink, R. Delwel, B. Löwenberg and P.J. Valk. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood*. 2005; 106: 3747-3754 (joint publication with HOVON-4 and -32)

G.E. de Greef, W.L. van Putten, M. Boogaerts, P.C. Huijgens, L.F. Verdonck, E. Vellenga, M. Theobald, E. Jacky and B. Löwenberg; The Dutch-Belgian Hemato-Oncology Co-operative Group HOVON; The Swiss Group for Clinical Cancer Research SAKK. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. *British Journal of Haematology*, 2005; 128, 184-191. (joint publication with HOVON-4/4A)

D.A. Breems, W.L. van Putten, P.C. Huijgens, G.J. Ossenkoppele, G.E. Verhoef, L.F. Verdonck, E. Vellenga, G.E. de Greef, E. Jacky, J. van der Lelie, M.A. Boogaerts and B. Löwenberg. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *Journal of Clinical Oncology*. 2005; 23: 1969-1978 (joint publication with HOVON-4/4A)

S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelink, W.L. van Putten, P.J. Valk, S. van der Poel-van de Luytgaarde, R. Hack, R. Slater, E.M. Smit, H.B. Beverloo, G. Verhoef, L.F. Verdonck, G.J. Ossenkoppele, P. Sonneveld, G.E. de Greef, B. Löwenberg and R. Delwel. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. *Blood*. 2003; 101: 837-845 (joint publication with HOVON-4 and -31)

B. Löwenberg, W. van Putten, M. Theobald, J. Gmür, L. Verdonck, P. Sonneveld, M. Fey, H. Schouten, G. de Greef, A. Ferrant, T. Kovacsovic, A. Gratwohl, S. Daenen, P. Huijgens, M. Boogaerts; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. *The New England Journal of Medicine*. 2003; 349: 743-752

M.M. van den Heuvel-Eibrink, E.A. Wiemer, A. Prins, J.P. Meijerink, P.J. Vossebeld, B. van der Holt, R. Pieters and P. Sonneveld. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). *Leukemia*. 2002; 16: 833-839 (joint publication with HOVON-4)

M.M. van den Heuvel-Eibrink, E.A. Wiemer, M.J. de Boevere, B. van der Holt, P.J. Vossebeld, R. Pieters and P. Sonneveld. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. *Blood*. 2001; 97: 3605-3611 (joint publication with HOVON-4)

M.M. van den Heuvel-Eibrink, E.A. Wiemer, M.J. de Boevere, R.M. Slater, E.M. Smit, M.M. van Noesel, B. van der Holt, M. Schoester, R. Pieters and P. Sonneveld. MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. *Leukemia*. 2001; 15: 398-405 (joint publication with HOVON-4)

D.M. van der Kolk, E.G. de Vries, W.J. van Putten, L.F. Verdonck, G.J. Ossenkoppele, G.E.G. Verhoef and E. Vellenga. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. *Clinical Cancer Research*. 2000; 6: 3205-3214 (joint publications with HOVON-4)

H.J. Broxterman, P. Sonneveld, W.J. van Putten, J. Lankelma, C.A. Eekman, G.J. Ossenkoppele, H.M. Pinedo, B. Löwenberg and G.J. Schuurhuis. P-glycoprotein in primary acute myeloid leukemia and

treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. *Leukemia*. 2000; 14: 1018-1024

E. Vellenga, W.L.J. van Putten, M.A. Boogaerts, S.M.G.J. Daenen, G.E.G. Verhoef, A. Hagenbeek, A.R. Jonkhoff, P.C. Huijgens, L.F. Verdonck, J. van der Lelie, H.C. Schouten, J. Gmür, P. Wijermans, A. Gratwoh, U. Hess, M.F. Fey and B. Löwenberg. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. *Bone Marrow Transplantation*. 1999; 23: 1279-1282

HOVON 30 AML (02/95 - 02/00)

S. Daenen, B. van der Holt, G.E.G. Verhoef, B. Löwenberg, P.W. Wijermans, P.C. Huijgens, R. van Marwijk Kooy, H.C. Schouten, M.H.H. Kramer, A. Ferrant, E. van den Berg, M.M.C. Steijaert, L.F. Verdonck and P. Sonneveld. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. *Leukemia Research*. 2004; 28: 1057-1067

HOVON 31 AML (05/97 - 02/99)

M.M. van den Heuvel-Eibrink, B. van der Holt, A.K. Burnett, W.U. Knauf, M.F. Fey, G.E.G. Verhoef, E. Vellenga, G.J. Ossenkoppele, B. Löwenberg and P. Sonneveld. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. *Annals of Hematology*. 2007; 86: 329-337

B. van der Holt, D. Breems, H.B. Beverloo, E. van den Berg, A.K. Burnett, P. Sonneveld and B. Löwenberg. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. *British Journal of Haematology*. 2007; 136: 96-105

B. van der Holt, M.M. van den Heuvel-Eibrink, R.H.M. van Schaik, I.P. van der Heiden, E.A. Wiemer, P.J.M. Vossebeld, B. Löwenberg and P. Sonneveld. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. *Clinical Pharmacology and Therapeutics*. 2006; 80: 427-439

B. van der Holt, B. Löwenberg, A.K. Burnett, W.U. Knauf, J. Shepherd, P.P. Piccaluga, G.J. Ossenkoppele, G.E.G. Verhoef, A. Ferrant, M. Crump, D. Selleslag, M. Theobald, M.F. Fey, E. Vellenga, M. Dugan and P. Sonneveld, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative group (HOVON) and the United Kingdom Medical Research Council (MRC). The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. *Blood*. 2005; 106: 2646-2654

M.M. van den Heuvel-Eibrink, B. van der Holt and P. Sonneveld. Role of BCRP and its expression with MDR1 in adult AML. *Leukemia Research*. 2005; 29: 115

S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelinck, W.L. van Putten, P.J. Valk, S. van der Poel-van de Luytgaarde, R. Hack, R. Slater, E.M. Smit, H.B. Beverloo, G. Verhoef, L.F. Verdonck, G.J. Ossenkoppele, P. Sonneveld, G.E. de Greef, B. Löwenberg and R. Delwel. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. *Blood*. 2003; 101: 837-845 (joint publication with HOVON-4 and -29)

HOVON 32 MDS / Elderly AML (10/96 - 01/01)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (joint publication with HOVON-4, -10, -29, -42 and -43)

R.G. Verhaak, C.S. Goudswaard, W. van Putten, M.A. Bijl, M.A. Sanders, W. Hagens, A.G. Uitterlinden, C.A. Erpelinck, R. Delwel, B. Löwenberg and P.J. Valk. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood*. 2005; 106: 3747-3754 (joint publication with HOVON-4 and -29)

G.J. Ossenkoppele W.J. Graveland, P. Sonneveld, S.M.G.J. Daenen, D.H. Biesma, L.F. Verdonck, R. Schaafsma, P.H.M. Westveer, F. Peters, P. Noordhuis, P. Muus, R. van der Holt, M. Delforge, B. Löwenberg and G.E.G. Verhoef, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. *Blood*. 2004; 103: 2908-2913

HOVON 42/42A AML / SAKK 30/00 (HO42: 01/01 - 02/07; HO42A: 01/06 - 10/08)

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerd O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol*. 2013; 31: 3889-3897

A. Leunis, W.K. Redekop, K.A.G.M. van Montfort, B. Löwenberg and C.A. Uyl-de Groot. The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia. *Pharmacoeconomics*. 2013; 31: 605–621 (joint publication with HOVON-4 and -29)

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013; 122: 1576-1582 (joint publication with HOVON-4/4A, -29 and -92)

Breems DA, Van Putten WL, Löwenberg B. The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. *Blood*. 2013; 121: 3056-3057 (joint publication with HOVON-29 and -29)

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013; 121: 2424-2431 (joint publication with HOVON-4/4A, -29, -43 and -92)

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. *J Clin Oncol*. 2013; 31: 95-103 (joint publication with HOVON-4/4A, -29, -42/42A, -43 and -92)

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *Journal of Clinical Oncology*. 2012; 30: 2140-2146 (joint publication with HOVON-4/4A and -29)

Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK). Favorable effect of priming with

granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. *Blood*. 2012; 119: 5367-5373

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF and Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. *Blood*. 2011; 118: 6037-6042 (*joint publication with HOVON-29*)

Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Löwenberg B and Valk PJ. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. *Blood*. 2011; 118: 1069-1076 (*joint publication with HOVON-4/4A and -29*)

Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J and Ganser A. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. *Blood*. 2011; 117: 4561-4568 (*joint publication with HOVON-4/4A and -29*)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J and Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. *The New England Journal of Medicine*. 2011;364: 1027-1036

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruitter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B and Döhner H. Clinical, molecular, and prognostic significance of WHO type $inv(3)(q21q26.2)/t(3;3)(q21;q26.2)$ and various other 3q abnormalities in acute myeloid leukemia. *Journal of Clinical Oncology*. 2010; 28: 3890-3898 (*joint publication with HOVON-4/4A, -29 and -43*)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (*joint publication with HOVON-4/4A, -18, -29, -37, -43, -51, -70 and -71*)

Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwien K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K and Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *Journal of Clinical Oncology*. 2010; 28: 2101-2107 (*joint publication with HOVON-4/4A and -29*)

Figuroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, Valk PJ, Löwenberg B, Delwel R and Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell*. 2010; 17: 13-27 (*joint publication with HOVON-4/4A, -29 and -43*)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (*joint publication with HOVON-4, -10, -29, -32 and -43*)

D.A. Breems, W.L. van Putten, G.E. de Greef, S.L. van Zelderen-Bhola, K.B. Gerssen-Schoorl, C.H. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeyer, H.B. Beverloo and B. Löwenberg. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *Journal of Clinical Oncology*. 2008; 26: 4791-4797 (*joint publication with HOVON-4/4A and -29*)

J.J. Cornelissen, W.L.J. van Putten, L.F. Verdonck, M. Theobald, E. Jacky, S.M. Daenen, M. van Marwijk Kooy, P. Wijermans, H. Schouten, P.C. Huijgens, H. van der Lelie, M. Fey, A. Ferrant, J. Maertens, A. Gratwohl and B. Löwenberg. Myeloablative HLA-identical sibling stem cell transplantation in first remission

acute myeloid leukemia in young and middle aged adults: benefits for whom? results of a HOVON/SAKK donor versus no donor analysis. *Blood*. 2007; 109: 3658-3666 (joint publication with HOVON-4/4A and -29)

HOVON 43 AML (10/00 - 06/06)

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013; 121: 2424-2431 (joint publication with HOVON-4/4A, -29, -42/42A and -92)

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. *J Clin Oncol*. 2013; 31: 95-103 (joint publication with HOVON-4/4A, -29, -42/42A, -43 and -92)

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruyter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B and Döhner H. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *Journal of Clinical Oncology*. 2010; 28: 3890-3898 (joint publication with HOVON-4/4A, -29 and -42)

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (joint publication with HOVON-4/4A, -18, -29, -37, -42/42A, -51, -70 and -71)

B. Löwenberg, J. Beck, C. Graux, W. van Putten, H.C. Schouten, L.F. Verdonck, A. Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Döhner, A. Gratwohl, T. Pabst, G.J. Ossenkoppele and J. Maertens; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood*. 2010; 115: 2586-2591

Figuroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, Valk PJ, Löwenberg B, Delwel R and Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell*. 2010; 17: 13-27 (joint publication with HOVON-4/4A, -29 and -42)

Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ and Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009; 113: 3088-3091 (joint publication with HOVON-4, -10, -29, -32 and -42)

B. Löwenberg, G.J. Ossenkoppele, W. van Putten, H.C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, M. van Marwijk Kooy, L.F. Verdonck, J. Beck, H. Döhner, A. Gratwohl, T. Pabst and G. Verhoef; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. *The New England Journal of Medicine*. 2009. 361: 1235-1248

HOVON 52 APL (11/96 - 06/05)

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J,

Manso F, Amador ML, Vellenga E, Lowenberg B and Sanz MA; PETHEMA; HOVON Groups. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. *Haematologica*. 2011; 96: 1470-1477

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B and Sanz MA; PETHEMA; HOVON Groups. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. *Blood*. 2011; 117: 1799-1805 (joint publication with HOVON-79)

Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, Ossenkoppele GJ, Peñarrubia MJ, Pérez-Encinas M, Bergua J, Debén G, Sayas MJ, de la Serna J, Ribera JM, Bueno J, Milone G, Rivas C, Brunet S, Löwenberg B and Sanz M. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. *Journal of Clinical Oncology*. 2010; 28: 3872-3879 (joint publication with HOVON-79)

Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B and Sanz MA. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. *Haematologica*. 2010; 95: 424-431

Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V, Pérez I, Fernández I, Viguria M, Rayón C, González J, de la Serna J, Esteve J, Bergua JM, Rivas C, González M, González JD, Negri S, Brunet S, Lowenberg B, Sanz MA. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. *Haematologica*. 2009; 94: 1242-1249

P. Montesinos, J.M. Bergua, E. Vellenga, C. Rayón, R. Parody, J. de la Serna, A. León, J. Esteve, G. Milone, G. Debén, C. Rivas, M. González, M. Tormo, J. Díaz-Mediavilla, J.D. González, S. Negri, E. Amutio, S. Brunet, B. Lowenberg and M.A. Sanz. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. *Blood*. 2009; 113: 775-783

Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, Bergua JM, León A, Negri S, González M, Rivas C, Esteve J, Milone G, González JD, Amutio E, Brunet S, García-Laraña J, Colomer D, Calasanz MJ, Chillón C, Barragán E, Bolufer P, Löwenberg B. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. *Blood*. 2008; 112: 3130-3134

de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B and Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. *Blood*. 2008; 111: 3395-3402

HOVON 60 MDS / SAKK 33/99 (11/01 - 10/06)

Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A and Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. *Journal of Clinical Oncology*. 2011; 29: 303-309

HOVON 79 APL / PETHEMA LPA 2005 (07/05 - 04/09)

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B and Sanz MA; PETHEMA; HOVON Groups. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. *Blood*. 2011; 117: 1799-1805 (joint publication with HOVON-52)

Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, Ossenkoppele GJ, Peñarrubia MJ, Pérez-Encinas M, Bergua J, Debén G, Sayas MJ, de la Serna J, Ribera JM, Bueno J, Milone G, Rivas C, Brunet S, Löwenberg B and Sanz M. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. *Journal of Clinical Oncology*. 2010; 28: 3872-3879 (joint publication with HOVON-52)

Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD and Löwenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. *Blood*. 2010; 115: 5137-5146

HOVON 81 AML / SAKK (02/07 - 08/09)

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerd O, Wijermans P, Passweg JR, Löwenberg B. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). *Blood*. 2012; 120: 4706-4711

Ossenkoppele GJ, Löwenberg B. HOVON 81: fase II-studie naar tolerantie en effectiviteit van de toevoeging van bevacizumab aan standaard therapie voor patiënten met AML. *Nederlands Tijdschrift voor Hematologie*. 2007; 4: 308-309

HOVON 89 MDS (05/09 - ongoing)

Van de Loosdrecht AA. De HOVON 89: de eerste HOVONstudie voor het laag- en intermediair-Irisico myelodysplastisch syndroom; de rol van lenalidomide met of zonder erythropoëetine en G-CSF. *Nederlands Tijdschrift voor Hematologie*. 2009; 6: 151-154

HOVON 92 AML / SAKK 30/08 (10/08 - 02/10)

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013; 122: 1576-1582 (joint publication with HOVON-4/4A, -29 and -42/42A)

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013; 121: 2424-2431 (joint publication with HOVON-4/4A, -29, -42/42A and -43)

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwien K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. *J Clin Oncol*. 2013; 31: 95-103 (joint publication with HOVON-4/4A, -29, -42/42A, -43 and -92)

Ossenkoppele GJ, Löwenberg B. HOVON 92: toevoeging van laromustine (Cloretazine®) aan standaard remissie-inductie chemotherapie bij patiënten jonger dan 65 jaar met AML en MDS (RAEB met IPSS>1,0). *Nederlands Tijdschrift voor Hematologie*. 2009; 6: 32-33

HOVON 97 AML (06/09 - ongoing)

Huls G, Vellenga E. HOVON 97: een prospectief gerandomiseerde studie om het effect van onderhoudsbehandeling met azacitidine te onderzoeken bij oudere patiënten met acute myeloïde leukemie. *Nederlands Tijdschrift voor Hematologie*. 2009; 6: 276-278

HOVON 102 AML (01/10 - ongoing)

Ossenkoppele GJ, Löwenberg B. HOVON 102: toevoeging van clofarabine aan standaard remissie-inductie chemotherapie bij patiënten jonger dan 65 jaar met acute myeloïde leukemie en myelodysplastisch syndroom (RAEB met IPSS $\geq 1,5$). *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 69-71

HOVON 103 AML (06/10 - ongoing)

Ossenkoppele GJ, Löwenberg B. HOVON 103: fase II-studies naar tolerantie en effectiviteit van de toevoeging van nieuwe geneesmiddelen aan standaardtherapie voor oudere patiënten met acute myeloïde leukemie Het Octopus-ontwerp. *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 241-244

Reviews & guidelines

Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol*. 2012; 9: 579-590

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B and Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010; 115: 453-474

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK and Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*. 2009; 113: 1875-1891

Chronic Lymphoid Leukemia (CLL)

HOVON 68 CLL (12/05 – 11/10)

Schaafsma MR, Wittebol S. HOVON 68: de eerste HOVON-studie voor patiënten met B-cel-chronische lymfatische leukemie. *Nederlands Tijdschrift voor Hematologie*. 2005; 2: 154

HOVON 88 CLL (11/08 – 12/12)

Van Gelder M. De HOVON 88-studie: 'intention-to-treat' fase II-studie naar het effect van remissie-inductie en allogene stamceltransplantatie bij hoogrisico chronische lymfatische leukemie. *Nederlands Tijdschrift voor Hematologie*. 2009; 6: 111-115

HOVON 101 CLL (04/10 - ongoing)

van Oers MH. HOVON 101: een fase III, open label, gerandomiseerde multicentrische studie naar ofatumumab-onderhoudsbehandeling bij patiënten met een recidief chronische lymfatische leukemie die in partiële of complete remissie zijn na re-inductiebehandeling. *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 294-296

HOVON 109 CLL (09/11 - ongoing)

Kater AP, Chamuleau ME, Posthuma W, Schipperus MR, Spiering M, van Oers MH. HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patiënten en patiënten met comorbiditeit; een fase I/II-studie. *Nederlands Tijdschrift voor Hematologie*. 2012; 9: 197-201

Reviews & guidelines

te Raa GD, van Oers MH, Kater AP; HOVON CLL working party. Monoclonal B-cell lymphocytosis: incidence, riskstratification and recommendations for daily practice [Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2012; 9: 138-146

te Raa GD, van Oers MH, Kater AP; HOVON CLL working party. Monoclonal B-cell lymphocytosis: recommendations from the Dutch Working Group on CLL for daily practice. *The Netherlands Journal of Medicine*. 2012; 70: 236-241

Kater AP, Wittebol S, Chamuleau ME, van Gelder M and J van Oers MH, Hovon CLL Working Party. Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. *The Netherlands Journal of Medicine*. 2011; 69: 422-429

Chronic Myeloid Leukemia (CML)

HOVON 20 CML (10/93 - 05/01)

H.C. Kluin-Nelemans, G. Buck, S. le Cessie, S. Richards, H.B. Beverloo, J.H. Falkenburg, T. Littlewood, P. Muus, D. Bareford, H. van der Lelie, A.R. Green, K.J. Roozendaal, A.E. Milne, C.S. Chapman and P. Shepherd; MRC and HOVON groups. Randomized comparison of low-dose versus high-dose interferon- α in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. *Blood*. 2004; 103: 4408-4415

HOVON 38 CML (01/98 - 06/01)

W. Deenik, B. van der Holt, G.E.G. Verhoef, A.V.M.B. Schattenberg, L.F. Verdonck, S.M.G.J Daenen, P. Zachee, P.H.M. Westveer, W.M. Smit, S. Wittebol, H.C. Schouten, B. Löwenberg, G.J. Ossenkoppele and J.J. Cornelissen. High-vs low-dose cytarabine combined with interferon α in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. *Annals of Hematology*. 2007; 86: 117-125

HOVON 51 CML (08/01 - 11/05)

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkoppele GJ, Janssen JJ. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). *Eur J Cancer*. 2013; 49: 3242-3246

Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M and Hehlmann R. The EUTOS CML score aims to support clinical decision-making. *Blood*. 2012; 119: 2966-2967

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M and Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. *Blood*. 2011; 118: 686-692

Deenik W, Cornelissen JJ. Preventie van resistentie bij chronische myeloïde leukemie: resultaten van de HOVON 51-studie, waarin imatinib en cytarabine werden gecombineerd. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 117-124

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B and Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116: 2122-2126 (*joint publication with HOVON-4/4A, -18, -29, -37, -42/42A, -43, -70 and -71*)

Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ, van der Heiden IP, Sonneveld P, van Schaik RH and Cornelissen JJ. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. *Blood*. 2010; 116: 6144-6145

Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ and Cornelissen JJ. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. *Haematologica*. 2010; 95: 914-921

Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ and Cornelissen JJ. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. *Blood*. 2008; 111: 2581-2588

HOVON 78 CML (05/06 - 05/10)

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. *Ann Hematol.* 2013; 92: 1049-1056

Ossenkoppele GJ, Cornelissen JJ. HOVON 78: prospectief gerandomiseerd onderzoek naar de combinatie van imatinib en cytarabine in vergelijking met imatinib alleen. *Nederlands Tijdschrift voor Hematologie.* 2007; 4: 70-71

Reviews & guidelines

Ossenkoppele GJ, Janssen JJ, Posthuma EF, Falkenburg JH, Bos GM, Petersen EJ, Schattenberg AV, Verhoef GE, Vellenga E, Cornelissen JJ. Aanbevelingen voor de behandeling van chronische myeloïde leukemie namens de HOVON Leukemie Werkgroep. *Nederlands Tijdschrift voor Hematologie.* 2010; 7: 198-206

Follicular lymphoma (FL)

HOVON 39 NHL / EORTC 20981 (11/98 - 10/05)

van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *Journal of Clinical Oncology*. 2010; 28: 2853-2858

van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. *Journal of Clinical Oncology*. 2010; 28: 2246-2252

van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood*. 2006; 108: 3295-3301

HOVON 48 NHL-FIT (02/01 - 01/05)

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J and Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *Journal of Clinical Oncology*. 2008; 26: 5156-5164

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. *Journal of Clinical Oncology*. 2013; 31: 1977-1983

HOVON 73 NHL-PRIMA (12/04 – 04/07)

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B and Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011; 377: 42-51

Hagenbeek A. Rituximab-onderhoudsbehandeling bij patiënten met folliculair lymfoom in eerste remissie: de PRIMA/HOVON73-studie. *Nederlands Tijdschrift voor Hematologie*. 2006; 3: 77-79

HOVON 110 FL (09/11 – ongoing)

Kersten MJ, Doorduijn JK, Ghidry W, Spiering M, Steijaert M, Meulendijks I, Hagenbeek A. HOVON 110: ReBeL-studie: een gerandomiseerde fase I/II-studie naar de effectiviteit en veiligheid van behandeling met lenalidomide en rituximab, met of zonder bendamustine, bij volwassen patiënten met recidief folliculair lymfoom. *Nederlands Tijdschrift voor Hematologie*. 2012; 9: 71-75

Hairy cell leukemia (HCL)

HOVON 23 HCL (02/94 - 03/95)

J.M.M. Raemaekers, M.B. van't Veer and M.J.J.T. Bogman. Succesvolle ambulante behandeling van patiënten met harige-cellenleukemie met één cyclus van het purineanalogon cladribine. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group]. *Nederlands Tijdschrift voor Geneeskunde*. 1996; 140: 1600-1604

Mantle cell lymphoma (MCL)**HOVON 45 MCL** (03/01 - 11/04)

M.B. van 't Veer, D. de Jong, M. MacKenzie, H.C. Kluin-Nelemans, M.H. van Oers, J. Zijlstra, A. Hagenbeek and W.L. van Putten. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. *British Journal of Haematology*. 2009. 144: 524-530

HOVON 55 MCL (01/05 - 10/10)

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. *The New England Journal of Medicine*. 2012; 367: 520-531

Kluin-Nelemans JC, Van 't Veer MB. De HOVON 55-studie: ouderen met een mantelcelymfoom. *Nederlands Tijdschrift voor Hematologie*. 2006; 3: 116-118

HOVON 75 MCL (03/07 - 03/12)

Van 't Veer MB. HOVON 75: een nieuwe studie voor patiënten jonger dan 65 jaar met mantelcelymfoom. *Nederlands Tijdschrift voor Hematologie*. 2006; 3: 227-229

Multiple myeloma (MM) and amyloidosis

HOVON 16 MM (09/91 - 09/97)

C.G. Schaar, H.C. Kluin-Nelemans, C. te Marvelde, S. le Cessie, W.P. Breed, W.E. Fibbe, W.A. van Deijk, M.M. Fickers, K.J. Roozendaal and P.W. Wijermans; Dutch-Belgian Hemato-Oncology Cooperative Group HOVON. Interferon-alpha as maintenance therapy in patients with multiple myeloma. *Annals of Oncology*. 2005; 16: 634-639

C.G. Schaar, J.C. Kluin-Nelemans, S. le Cessie, P.F.H. Franck, M.C. te Marvelde and P.W. Wijermans. Early response to therapy and survival in multiple myeloma. *British Journal of Haematology*. 2004; 125: 162-166

HOVON 17 MM / EORTC 06914 (04/92 - 06/99)

P. Sonneveld, S. Suci, P. Wijermans, M. Beksac, R. Neuwirtova, G. Solbu, H. Lokhorst, J. van der Lelie, H. Döhner, H. Gerhartz, C.M. Segeren, R. Willemze and B. Löwenberg. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). A cooperative study from the European Organization for Research and Treatment of Cancer (EORTC) Leukaemia Cooperative Group (LCG) and the Dutch Haemato-Oncology Cooperative Study Group (HOVON). *British Journal of Haematology*. 2001; 115: 895-902

HOVON 24 MM (11/95 - 03/00)

P. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH and Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. *Haematologica*. 2007; 92: 928-935

C. Schilthuis, A. Broyl, B. van der Holt, Y. de Knecht, H. Lokhorst and P. Sonneveld. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. *Haematologica*. 2007; 92: 277-278

K.L. Wu, B. Beverloo, H.M. Lokhorst, C.M. Segeren, B. van der Holt, M.M.C. Steijaert, P.H.M. Westveer, P.J. Poddighe, G.E.G. Verhoef and P. Sonneveld; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC). Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. *British Journal of Haematology*. 2007; 136: 615-623

M. van Agthoven, C.M. Segeren, I. Buijt, C.A. Uyl-de Groot, B. van der Holt, H.M. Lokhorst and P. Sonneveld. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. *European Journal of Cancer*. 2004; 40: 1159-1169

H.M. Lokhorst, C.M. Segeren, L.F. Verdonck, B. van der Holt, R. Raymakers, M.H.J. van Oers, R.M.Y. Barge, H.C. Schouten, P.H.M. Westveer, M.M.C. Steijaert, J.J. Cornelissen and P. Sonneveld. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. *Journal of Clinical Oncology*. 2003; 21: 1728-1733

C.M. Segeren, P. Sonneveld, B. van der Holt, E. Vellenga, A.J. Croockewit, G.E.G. Verhoef, J.J. Cornelissen, M.R. Schaafsma, M.H.J. van Oers, P.W. Wijermans, W.E. Fibbe, S. Wittebol, H.C. Schouten, M. van Marwijk Kooy, D.H. Biesma, J.W. Baars, R. Slater, M.M.C. Steijaert, I. Buijt and H.M. Lokhorst. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. *Blood*. 2003; 101: 2144-2151

C.M. Segeren, P. Sonneveld, B. van der Holt, J.W. Baars, D.H. Biesma, J.J. Cornellissen, A.J. Croockewit, A.W. Dekker, W.E. Fibbe, B. Löwenberg, M. van Marwijk Kooy, M.H.J. van Oers, D.J. Richel, H.C. Schouten, E. Vellenga, G.E.G. Verhoef, P.W. Weijermans, S. Wittebol and H.M. Lokhorst. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated Multiple Myeloma. *British Journal of Haematology*. 1999; 105: 127-130

HOVON 41 AL Amyloidosis (09/00 - 01/06)

Lokhorst HM, Hazenberg BP and Croockewit A. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *The New England Journal of Medicine*. 2008; 358: 92

HOVON 49 MM (01/02 - 07/07)

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica*. 2013; 98: 980-987

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. *Haematologica*. 2013; 98: 87-94

Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P and Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. *Ann Hematol*. 2011; 90: 1427-1439

Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P and Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*. 2011; 118: 1239-1247

Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. *Journal of Clinical Oncology*. 2010; 28: 3160-3166

HOVON 50 MM / GMMG-HD3 (11/01 - 06/05)

Lokhorst HM, van der Holt B, Cornellissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerd O, Ammerlaan R, Sonneveld P. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. *Blood*. 2012; 119: 6219-6225; quiz 6399 (joint publication with HOVON-54)

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P and Morgan GJ. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. *Journal of Clinical Oncology*. 2011; 29: 797-804

Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. *Blood*. 2010; 116: 22-26 (joint publication with HOVON-65)

H.M. Lokhorst, B. van der Holt, S. Zweegman, E. Vellenga, S. Croockewit, M.H. van Oers, P. von dem Borne, P. Wijermans, R. Schaafsma, O. de Weerd, S. Wittebol, M. Delforge, H. Berenschot, G.M. Bos, K.S. Jie, H. Sinnige, M. van Marwijk-Kooy, P. Joosten, M.C. Minnema, R. van Ammerlaan and P. Sonneveld; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. *Blood*. 2010; 115: 1113-1120

Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, Van Ness B and Morgan GJ. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. *Blood*. 2008; 112: 4924-4934

Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerd O, Wijermans P, Wittebol S, Duersen U, Vellenga E and Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica*. 2008; 93: 124-127

I. Breitkreutz, H.M. Lokhorst, M.S. Raab, B. van der Holt, F.W. Cremer, D. Herrmann, A. Glasmacher, I.G. Schmidt-Wolf, I.W. Blau, H. Martin, H. Salwender, A. Haenel, P. Sonneveld and H. Goldschmidt. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. *Leukemia*. 2007; 21: 1294-1299

M.C. Minnema, I. Breitkreutz, J.J. Auwerda, B. van der Holt, F.W. Cremer, A.M. van Marion, P.H. Westveer, P. Sonneveld, H. Goldschmidt and H.M. Lokhorst. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. *Leukemia*. 2004;18: 2044-2046

H. Goldschmidt, P. Sonneveld, F.W. Cremer, B. van der Holt, P. Westveer, I. Breitkreutz, A. Benner, A. Glasmacher, I.G.D. Schmidt-Wolf, H. Martin, D. Hoelzer, A.D. Ho and H.M. Lokhorst. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. *Annals of Hematology*. 2003; 82: 654-659

HOVON 54 MM (06/03 – 11/06)

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerd O, Ammerlaan R, Sonneveld P. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. *Blood*. 2012; 119: 6219-6225; quiz 6399 (joint publication with HOVON-50)

HOVON 65 MM / GMMG-HD4 (04/05 - 05/08)

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. *Haematologica*. 2014; 99: 148-154

Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P; Dutch-Belgian HOVON group and the German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. *Blood*. 2013; 121: 624-627

Kuiper R, Broyl A, de Knecht Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. A gene expression signature for high-risk multiple myeloma. *Leukemia*. 2012; 26: 2406-2413

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Dührsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. *Journal of Clinical Oncology*. 2012; 30: 2946-2955

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P and Goldschmidt H. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. *Blood*. 2012; 119: 940-948

van Duin M, Broyl A, de Knecht Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS and Sonneveld P. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. *Haematologica*. 2011; 96: 1662-1669

Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ and Avet-Loiseau H. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. *Haematologica*. 2011; 96: 1728-1732

Corthals SL, Sun SM, Kuiper R, de Knecht Y, Broyl A, van der Holt B, Beverloo HB, Peeters JK, el Jarari L, Lokhorst HM, Zweegman S, Jongen-Lavrencic M and Sonneveld P. MicroRNA signatures characterize multiple myeloma patients. *Leukemia*. 2011; 25: 1784-1789

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knecht Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H and Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. *Lancet Oncology*. 2010; 11: 1057-1065

Broyl A, Hose D, Lokhorst H, de Knecht Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M and Sonneveld P. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. *Blood*. 2010; 116: 2543-2553

Libourel EJ, Sonneveld P, van der Holt B, de Maat MP, Leebeek FW. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. *Blood*. 2010; 116: 22-26 (joint publication with HOVON-50)

HOVON 76 MM (12/07 - 03/10)

Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Buijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T and Minnema MC. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. *Blood*. 2011; 118: 2413-2419

HOVON 87 MM / NMSG 18 (01/09 - 10/12)

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncology*. 2014; 15: 333-342

Zweegman S, Bos GM, Sonneveld P. De gerandomiseerde fase III HOVON 87-studie: melfalan, prednison, thalidomide versus melfalan, prednison, lenalidomide. *Nederlands Tijdschrift voor Hematologie*. 2008; 5: 335-338

EMN02 / HOVON 95 MM (01/11 – 04/13)

Sonneveld P. Nieuwe middelen bij de behandeling van jonge patiënten met multipel myeloom: de nieuwe HOVON 95-studie. *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 153-162

HOVON 104 AL Amyloidosis (01/12 - ongoing)

Minnema MC, Hazenberg EP. Trends in trials: HOVON 104. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 355-359

HOVON 108 MM (07/11 – 09/13)

Lokhorst HM, von dem Borne PA, Kersten MJ. HOVON 108: T-cel-gedepleteerde nietmyeloablatieve allogene stamceltransplantatie gevolgd door vroege consolidatie met lenalidomide of lenalidomide gecombineerd met bortezomib en aanvullend donorlymfocyteninfusie voor patiënten met een eerste recidief of progressie na eerstelijnsbehandeling. *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 332-338

HOVON 123 MM (01/14 - ongoing)

Zweegman S, Levin M-D, van de Donk NW, Ghidylemayehu W, Sonneveld P. [‘Feasibility’ en effectiviteit van melfalan-prednison-bortezomib (MPV) bij patiënten ≥ 75 jaar met een nieuw gediagnosticeerd multipel myeloom; een niet-gerandomiseerde fase II-studie.] Feasibility and efficacy of melphalan-prednisone-bortezomib (MPV) in newly diagnosed multiple myeloma patients ≥ 75 years; a non-randomized phase II trial [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2014; 11: 29-32

Reviews & guidelines

M.C. Minnema, B.P.C. Hazenberg, A. Croockewit, S. Zweegman, M.J. Kersten, P. Sonneveld, P.A. von dem Borne, G. Bos, E. van de Waal, E. Vellenga and H.M. Lokhorst. [De behandeling van AL-amyloïdose in Nederland anno 2013. Adviezen van de HOVON-werkgroep Multipel Myeloom] The treatment of AL amyloidosis in the Netherlands in 2013 [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2013; 10: 165-179

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party. Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. *Neth J Med*. 2013; 71: 54-62

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ, namens de HOVON Multipel Myeloomwerkgroep en de HOVON Lymfoomwerkgroep. Richtlijn voor diagnostiek en behandeling van de ziekte van Waldenström. *Nederlands Tijdschrift voor Hematologie*. 2012; 9: 219-231

J. Ruinemans-Koerts, J.G. Boonstra, I.S. Klasen, S. Zweegman, M.C. Minnema, J.J. Wegman, M.J. Kersten, R.B. Dinkelaar, P. Wijermans and R.A.P. Raymakers. [Laboratoriumonderzoek bij monoklonale gammopathie: detectie van monoklonale immuunglobulinen. NVKC/CMI/HOVON-richtlijn] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 160-168

S. Zweegman, M.C. Minnema, M. Stevens-Kroef, M.J. Kersten, P. Wijermans, J.J. Wegman, J.C. Regelink, R.A. Brooimans, B. Beverloo, A.C. Bloem, H.M. Lokhorst, P. Sonneveld and R.A.P. Raymakers, namens de HOVON Multipel Myeloom Werkgroep en de HOVON Werkgroep Hemato-oncologische Genoom Diagnostiek. [Diagnostiek bij multipel myeloom: de rol van beeldvorming, chromosoomanalyse en multiparameterflowcytometrie] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 146-158

P. Sonneveld, S. Zweegman, E. Vellenga, S. Wittebol, H.A.M. Sinnige, E. Meijer, M.C. Minnema and H.M. Lokhorst, namens de HOVON Myeloom Werkgroep. [Richtlijnen behandeling plasmacelaandoeningen anno 2010] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2010; 7: 84-95

H.M. Lokhorst, S. Zweegman, M.J. Kersten, R.A.P. Raymakers, E. Vellenga, S. Wittebol and P.Sonneveld, namens de HOVON-myeloomwerkgroep. [Richtlijnen behandeling multiple myeloom anno 2008] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie*. 2008; 5: 150-156

Haas RL, van der Maazen RW, Meerwaldt JH, Noordijk EM and van der Linden YM. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)] [Article in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*. 2005; 149: 1653

H. Lokhorst, P.C. Huijgens, R. Raymakers, G.M.J. Bos, E. Vellenga, P.W. Wijermans and P. Sonneveld; Myeloomwerkgroep van de Stichting Hemato-Oncologie voor Volwassenen Nederland. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)] [Article in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*. 2005; 149: 808-813

H.M. Lokhorst, P.Sonneveld, P.W. Wijermans and C.M. Segeren. [Multiple myeloma; treatment in the year 1998] [Article in Dutch]. *Nederlands Tijdschrift voor Geneeskunde*. 1998; 142: 1596-1602

Non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)

HOVON 3 NHL (01/87 - 04/94)

G.M.J. Bos, W.L.J. van Putten, B. van der Holt, M. van den Bent, L.F. Verdonck and A. Hagenbeek on behalf of the Dutch HOVON group. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? *Annals of Oncology*. 1998; 9: 191-194

C.A. Uyl-de Groot, A. Hagenbeek, L.F. Verdonck, B. Löwenberg and R.F. Rutten. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). *Bone Marrow Transplantation*. 1995; 16: 463-470 [no .PDF; abstract only]

L.F. Verdonck, W.L.J. van Putten, A. Hagenbeek, H.C. Schouten, P. Sonneveld, G.W. van Imhoff, H.C. Kluijn-Nelemans, J.M.M. Raemaekers, R.H.J. van Oers, H.L. Haak, R. Schots, A.W. Dekker, G.C. de Gast and B. Löwenberg. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. *The New England Journal of Medicine*. 1995; 332: 1045-1051

HOVON 7 NHL (PARMA-trial) (07/87 - 06/94)

J.-Y. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron, C. Guglielmi, A. Hagenbeek, R. Somers, F. Chauvin and T. Philip. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. *Blood*. 1998; 92: 3562-3568

C. Guglielmi, F. Gomez, T. Philip, A. Hagenbeek, M. Martelli, C. Sebban, N. Milpied, D. Bron, J.Y. Cahn, R. Somers, P. Sonneveld, C. Gisselbrecht, H. van der Lelie and F. Chauvin. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. *Journal of Clinical Oncology*. 1998; 16: 3264-3269

T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. van der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.Y. Cahn, J.L. Harousseau, B. Coiffier, P. Biron, F. Mandelli and F. Chauvin. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *The New England Journal of Medicine*. 1995; 333: 1540-1545

HOVON 15 NHL (04/91 - 01/94)

H.C. Schouten, W. Qian, S. Kvaloy, A. Porcellini, H. Hagberg, H.E. Johnson, J.K. Doorduijn, M.R. Sydes and G. Kvalheim. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. *Journal of Clinical Oncology*. 2003; 21: 3918-3927

I.C. Schouten, J.J.M. Raemaekers, H.C. Kluijn-Nelemans, H. van Kamp, W.A.M. Mellink and M.B. van't Veer. Dutch HOVON group. High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin's lymphoma. *Annals of Hematology*. 1996; 73: 273-277

HOVON 19 NHL (04/93 - 01/97)

A. Hagenbeek, H. Eghbali, S. Monfardini, U. Vitolo, P.J. Hoskin, C. de Wolf-Peeters, K. MacLennan, E. Staab-Renner, J. Kalmus, A. Schott, I. Teodorovic, A. Negrouk, M. van Glabbeke and R. Marcus. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. *Journal of Clinical Oncology*. 2006; 24: 1590-1596

HOVON 22 HD/NHL (09/94 - 09/98)

M. van Agthoven, E. Vellenga, W.E. Fibbe, T. Kingma and C.A. Uyl-de Groot. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or

autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. *European Journal of Cancer*. 2001; 37: 1781-1789

E. Vellenga, M. van Agthoven, A.J. Croockewit, L.F. Verdonck, P.J. Wijermans, M.H. van Oers, C.P. Volkers, G.W. van Imhoff, T. Kingma, C.A. Uyl-de Groot and W.E. Fibbe. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. *British Journal of Haematology*. 2001; 114: 319-326

HOVON 25 NHL (08/94 - 09/00)

Rayman N, Lam KH, van der Holt B, Koss C, Veldhuizen D, Budel LM, Mulder AH, Verdonck LF, Delwel R, de Jong D, van Imhoff GW and Sonneveld P. Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. *Clinical Lymphoma, Myeloma & Leukemia*. 2011; 11: 23-32 (joint publication with HOVON-26)

J.K. Doorduijn, I. Buijt, B. van der Holt, M. van Agthoven, P. Sonneveld and C.A. Uyl-de Groot. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. *Haematologica*. 2004; 89: 1109-1117

J.K. Doorduijn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, M.M.C. Steijaert, I. Buijt, C.A. Uyl-de Groot, M. van Agthoven, A.H. Mulder and P. Sonneveld for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. *Journal of Clinical Oncology*. 2003; 21: 3041-3050

HOVON 26 NHL (11/94 - 4/04)

Rayman N, Lam KH, van der Holt B, Koss C, Veldhuizen D, Budel LM, Mulder AH, Verdonck LF, Delwel R, de Jong D, van Imhoff GW and Sonneveld P. Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. *Clinical Lymphoma, Myeloma & Leukemia*. 2011; 11: 23-32 (joint publication with HOVON-25)

L.F. Verdonck, A. Notenboom, D.D. de Jong, M.A. Mackenzie, G.E.G. Verhoef, M.H.H. Kramer, G.J. Ossenkoppele, J.K. Doorduijn, P. Sonneveld and G.W. van Imhoff. Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin's Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). *Blood*. 2007; 109: 2759-2766

HOVON 27 NHL, including pilot (07/94 - 04/03)

G.W. van Imhoff, E.J. Boerma, B. van der Holt, E. Schuurin, L.F. Verdonck, H.C. Kluin-Nelemans and P.M. Kluin. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. *Journal of Clinical Oncology*. 2006; 24: 4135-4142 (joint publication with HOVON-40)

G.W. van Imhoff, B. van der Holt, M.A. MacKenzie, M.B. van't Veer, P.W. Wijermans, G.J. Ossenkoppele, H.C. Schouten, P. Sonneveld, M.M.C. Steijaert, P.M. Kluin, H.C. Kluin-Nelemans and L.F. Verdonck. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group studies 27 and 40. *Journal of Clinical Oncology*. 2005; 23: 3793-3801 (joint publication with HOVON-40)

G.W. van Imhoff, B. van der Holt, M.A. MacKenzie, G.J. Ossenkoppele, P.W. Wijermans, M.H.H. Kramer, M.B. van't Veer, H.C. Schouten, M. van Marwijk Kooy, M.H.J. van Oers, J.M.M. Raemaekers, P. Sonneveld, L.A.M.H. Meulendijks, P.M. Kluin, H.C. Kluin-Nelemans and L.F. Verdonck. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. *Leukemia*. 2005; 19: 945-952

HOVON 40 NHL (02/99 - 11/01)

G.W. van Imhoff, E.J. Boerma, B. van der Holt, E. Schuurin, L.F. Verdonck, H.C. Kluin-Nelemans and P.M. Kluin. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. *Journal of Clinical Oncology*. 2006; 24: 4135-4142 (joint publication with HOVON-27)

G.W. van Imhoff, B. van der Holt, M.A. MacKenzie, M.B. van't Veer, P.W. Wijermans, G.J. Ossenkuppele, H.C. Schouten, P. Sonneveld, M.M.C. Steijaert, P.M. Kluin, H.C. Kluin-Nelemans and L.F. Verdonck. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group studies 27 and 40. *Journal of Clinical Oncology*. 2005; 23: 3793-3801 (joint publication with HOVON-27)

HOVON 44 NHL (11/00 - 12/05)

Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ and Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. *Blood*. 2008; 111: 537-543

HOVON 47 NHL (06/01 - 10/03)

R.L. Haas and T. Girinsky. HOVON 47/EORTC 20013: chlorambucil vs 2x2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. *Annals of Hematology*. 2003; 82: 458-462

HOVON 69 T-NHL (11/05 - 11/07)

Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J and van Imhoff GW. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. *Annals of Oncology*. 2011; 22: 1595-1600

HOVON 77 NHL (05/06 - 06/10)

Zijlstra JM. Zevalin® voor oudere patiënten met een diffuus grootcellig B-celmyeloom en PET-positieve partiële remissie na rituximab-CHOP: de HOVON 77-studie. *Nederlands Tijdschrift voor Hematologie*. 2006; 3: 191-192

HOVON 84 NHL (10/07 - 04/12)

Lugtenburg PJ, Zijlstra JM. HOVON 84: intensivering en onderhoud met rituximab bij oudere patiënten met een diffuus grootcellig B-cel non-hodgkinlymfoom. *Nederlands Tijdschrift voor Hematologie*. 2007; 4: 271-273

HOVON 85 NHL (08/08 - 03/12)

Lugtenburg PJ, Brouwer RE, GW van Imhoff. De HOVON 85-studie: Zevalin®-consolidatietherapie na rituximab-PECC remissie-inductietherapie bij patiënten met een recidief of refractair agressief B-celmyeloom. *Nederlands Tijdschrift voor Hematologie*. 2008; 5: 287-289

HOVON 90 T-NHL (04/09 – 12/13)

Kluin-Nelemans JC, Van Imhoff GW. De HOVON 90- en 91-studies: gerandomiseerde studies voor jong en oud met een agressief T-NHL. *Nederlands Tijdschrift voor Hematologie*. 2008; 5: 339-341 (joint publication with HOVON-91)

HOVON 91 T-NHL (04/09 – 09/13)

Kluin-Nelemans JC, Van Imhoff GW. De HOVON 90- en 91-studies: gerandomiseerde studies voor jong en oud met een agressief T-NHL. *Nederlands Tijdschrift voor Hematologie*. 2008; 5: 339-341 (joint publication with HOVON-90)

HOVON 105 PCNSL / ALLG NHL24 (07/10 - ongoing)

Doorduijn JK, Bromberg JE. HOVON 105: rituximab bij de behandeling van het primair centraal zenuwstelsel lymfoom - een gerandomiseerde fase III intergroupstudie. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 29-33

Reviews & guidelines

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ; HOVON Multiple Myeloma Working Party; HOVON Lymphoma Working Party. Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. *Neth J Med*. 2013; 71: 54-62

Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ, namens de HOVON Multipel Myeloomwerkgroep en de HOVON Lymfoomwerkgroep. Richtlijn voor diagnostiek en behandeling van de ziekte van Waldenström. *Nederlands Tijdschrift voor Hematologie*. 2012; 9: 219-231

Stem cell transplantation

HOVON 96 GVHD (04/10 – ongoing)

Meijer E, Janssen JJ, Huls G. HOVON 96: preventie en behandeling van ernstige graft-versus-hostziekte na allogene stamceltransplantatie, toegepast als consoliderende immuuntherapie bij patiënten met maligne hematologische ziekten - een prospectieve gerandomiseerde fase III-studie. *Nederlands Tijdschrift voor Hematologie*. 2011; 8: 80-85

Supportive care

HOVON 64 ITP (08/05 – 05/10)

Koene HR, Zwaginga JJ. Een fase-II-studie voor de evaluatie van rituximab bij de behandeling van refractaire chronische idiopatische (immune) trombocytopenische purpura. *Nederlands Tijdschrift voor Hematologie*. 2005; 2: 71-73

HOVON 82 SANQUIN (03/07 – 05/09)

Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A and van Rhenen DJ; Dutch - Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. *British Journal of Haematology*. 2010; 150: 209-217

General

Huijgens PC. Disease profiling in haemato-oncology. [Karakterisering van ziekte en zieke in de hemato-oncologie] [Article in Dutch] *Tijdschr Psychiatr.* 2012; 54: 921-925

Blommestein HM, Verelst SG, Huijgens PC, Blijlevens NM, Cornelissen JJ, Uyl-de Groot CA. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. *Ann Hematol.* 2012; 91: 1945-1952

P.C. Huijgens and B. Löwenberg. [Bij de mijlpaal van de HOVON 100-studie: verleden, heden en toekomst] [Article in Dutch]. *Nederlands Tijdschrift voor Hematologie.* 2009; 6: 231-235